Latest Breaking News On - Yuhong xu - Page 1 : comparemela.com

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting

HighField Biopharmaceuticals Announces Two Abstracts Accepted for the 2024 ASCO Annual Meeting
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesYuhong xuAmerican society of clinical oncologyField biopharmaceuticalsAmerican societyClinical oncology

HighField Biopharmaceuticals HF1K16 Phase 1a Data Suggests the New Immuno-Oncology Drug is Safe, Well-Tolerated and Efficacious in Solid Tumors

HANGZHOU, China (BUSINESS WIRE) Jan 8, 2024

Dan eramianDonald wyattYuhong xuBusiness development contactOpus biotech communicationsField biopharmaceuticalsMedia contactDevelopment contactBusiness wireNation world

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Doses First Patient in Phase 1 Trial of HFK1, a Unique Immunoliposome, for Treatment of HER2 low and HER2+ Cancers
lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.

United statesYuhong xuDonald wyattMary crowley cancer researchProduct serviceField biopharmaceuticals doses first patientUnique immunoliposomeField biopharmaceuticalsChief medicalExecutive medical director

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers

HighField Biopharmaceuticals Receives US FDA IND Clearance for Phase 1 Trial of Immunoliposome HF158K1 for Treatment of HER2 low and HER2+ Cancers
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Dan eramianYuhong xuDonald wyattHighfield bioBusiness development contactOpus biotech communicationsDrug administrationField biopharmaceuticalsInvestigational new drugField bioDevelopment contact

HighField Biopharmaceuticals HF1K16, a New Immuno-Oncology Drug, Shows Promise in Patients with Refractory Glioblastoma | Illinois

HANGZHOU, China (BUSINESS WIRE) May 31, 2023

Mccormick placeUnited statesHighfield bioDonald wyattYuhong xuDan eramianBusiness development contactAmerican society of clinical oncologyOpus biotech communicationsField biopharmaceuticalsAmerican societyClinical oncologyMyeloid derived suppressor cellsField bioMedia contactDevelopment contact